PROMETEX: Metabolically-instructed personalized therapy selection for prostate cancer

Prostate cancer is a complex disease for which treatments are often not effective due to the cancer’s high variability—both between patients and within individual tumors. To improve treatment outcomes, understanding the unique characteristics of each tumor at the cellular level is pivotal.

Research shows that changes in how cancer cells process energy—known as metabolic reprogramming—play a key role in disease progression and treatment resistance.

This project, funded by the Swiss National Fund, aims to develop personalized treatment strategies by studying prostate cancer cells’ metabolism at single-cell level.

Using patient-derived organoids (3D cell models) and advanced AI tools, we will build an Atlas of Metabolic States to predict how individual cancer cells respond to therapy.

Our research will lead to a powerful platform for personalized prostate cancer treatment, helping doctors choose the most effective therapies based on each patient’s unique tumor profile.

Collaborations

Department for BioMedical Research, Inselspital Bern Universität Bern, Switzerland
European Molecular Biology Laboratory EMBL, Germany